1 EXHIBIT 11 Statement Regarding Computation of Earnings Per Share DURAMED PHARMACEUTICALS, INC. AND SUBSIDIARIES Year Ended December 31 1996 1995 1994 Primary: Weighted average common shares outstanding 10,522,213 8,026,359 7,815,808 Assumed conversion of preferred shares to common shares * * 746,590 Net effect of dilutive stock options and warrants - based on the treasury stock method using the average market price * * 1,685,917 ------------ ------------ ------------ Totals 10,522,213 8,026,359 10,248,315 ============ ============ ============ Net (loss) income $(25,640,507) $ (1,113,687) $ 9,550,867 ============ ============ ============ Per share amount $ (2.44) $ (0.14) $ 0.93 ============ ============ ============ Fully diluted: Weighted average common shares outstanding 10,522,213 8,026,359 7,815,808 Assumed conversion of preferred shares to common shares * * 746,590 Net effect of dilutive stock options based on the treasury stock method using the year-end market price, if higher than average market price * * 1,947,297 ------------ ------------ ------------ Totals 10,522,213 8,026,359 10,509,695 ============ ============ ============ Net (loss) income $(25,640,507) $ (1,113,687) $ 9,550,867 ============ ============ ============ Per share amount $ (2.44) $ (0.14) $ 0.91 ============ ============ ============ <FN> * Conversion of stock options and preferred shares not assumed in the computations because their effect is antidilutive.